Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in P-Glycoprotein Inhibitors [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
CYCLOSPORINE 68,304 9,332 13.7% 14,257 3,257 45.2 yrs 56.5%
VENETOCLAX 53,724 15,763 29.3% 20,812 1,818 67.9 yrs 37.6%
AMIODARONE 25,143 3,845 15.3% 13,711 3,889 69.9 yrs 36.9%
CANAGLIFLOZIN 24,411 544 2.2% 9,503 979 57.8 yrs 49.1%
NILOTINIB 23,171 4,543 19.6% 4,846 683 56.5 yrs 47.7%
TICAGRELOR 22,885 2,951 12.9% 8,579 1,698 65.9 yrs 36.7%
RELUGOLIX 20,660 958 4.6% 1,699 37 72.4 yrs 1.4%
MIRABEGRON 20,618 1,338 6.5% 2,589 1,150 69.8 yrs 69.1%
CLARITHROMYCIN 18,945 987 5.2% 6,385 1,129 52.9 yrs 67.0%
RITONAVIR 11,980 1,190 9.9% 2,925 350 43.8 yrs 43.8%

Head-to-Head Comparisons

CYCLOSPORINE vs VENETOCLAX CYCLOSPORINE vs AMIODARONE CYCLOSPORINE vs CANAGLIFLOZIN CYCLOSPORINE vs NILOTINIB VENETOCLAX vs AMIODARONE VENETOCLAX vs CANAGLIFLOZIN VENETOCLAX vs NILOTINIB AMIODARONE vs CANAGLIFLOZIN AMIODARONE vs NILOTINIB CANAGLIFLOZIN vs NILOTINIB
← Back to P-Glycoprotein Inhibitors [MoA] Class side effects →